A Look At Boost Run (BRUN) Valuation After US$471.7 Million GPU Contract Announcement

Advertisement

Why the new GPU contract matters for Boost Run (BRUN)

The recent surge in interest around Boost Run (BRUN) centers on its new approximately US$471.7 million, three year GPU server rental and managed services agreement with Thinking Machines Lab, which commits the customer to multi year payments.

The contract covers 5,000 NVIDIA B300 GPUs deployed across Boost Run data centers, along with shared storage and CPU services, and adds a sizeable, time bound stream of contracted revenue to the company’s AI infrastructure business.

See our latest analysis for Boost Run.

Since completing its SPAC merger in May and reporting rapid revenue growth from GPU leasing and enterprise AI contracts, Boost Run’s share price return has been strong. The 30 day share price return is 105.37% and the year to date share price return is 185.47%, while the 1 year total shareholder return of 261.61% points to powerful momentum behind the recent US$471.7 million contract news, despite a 1 day share price decline of 6.28% to US$36.74.

If you want to see what else is moving in AI infrastructure, it could be worth scanning a wider peer set through our 48 AI infrastructure stocks

With BRUN up 185.47% year to date and trading above one analyst price target of US$27.50, the key question is whether this recent GPU deal still leaves upside on the table or if the market is already pricing in future growth.

Price to book of 292.9x, is it justified?

On simple P/B math, BRUN screens as very expensive, with a 292.9x multiple versus a peer average of 6.6x and a US IT sector average of 2.8x, even as the last close sits at $36.74 and above both the US$27.50 analyst target and the SWS DCF estimate of $3.04.

P/B compares the market value of a company to its accounting net assets, which can be a rough gauge of how much investors are willing to pay over the balance sheet for future cash flows. For a young, unprofitable AI infrastructure company like Boost Run, a high P/B usually reflects expectations around future revenue growth, progress toward profitability and the value investors place on scarce GPU capacity.

Here, the gap is wide. The 292.9x P/B stands far above the 6.6x peer average and the 2.8x broader US IT sector, while the SWS DCF model indicates a fair value of $3.04, materially below the current share price of $36.74. That combination suggests the market is assigning a very rich premium to BRUN relative to both asset value and modeled future cash flows.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book ratio of 292.9x (OVERVALUED)

However, investors also need to watch for contract concentration risk with Thinking Machines Lab and the ongoing loss of US$16.274 million, which could pressure sentiment.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another way to look at value

While the 292.9x P/B ratio makes Boost Run look very expensive relative to peers, the SWS DCF model points in the same direction, with an estimated fair value of $3.04 compared with the current $36.74 share price, which implies a very rich premium. The key issue is whether future execution can support that gap.

Look into how the SWS DCF model arrives at its fair value.

BRUN Discounted Cash Flow as at Jun 2026
BRUN Discounted Cash Flow as at Jun 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Boost Run for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Seeing this mix of strong share price momentum, rich valuation and both risks and rewards, how does it stack up for you today? Take a closer look at the details, weigh the upside against the concerns, and then check out the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop your research with just one fast moving stock. Broaden your watchlist with other clear ideas that suit your goals and risk comfort.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Boost Run might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:BRUN

Boost Run

Provides artificial intelligence cloud infrastructure and high-performance computing solutions.

High growth potential and fair value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
66 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
CSBT.F logo
AnimalDoctorKwon on Kuros Biosciences ·

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

Fair Value:US$342.1892.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
RZLV logo
European_Hidden_Gem_Stocks on Rezolve AI ·

⚡ Two-Minute Drill: Rezolve AI - The AI That Doesn't Recommend Products. It Buys Them.

Fair Value:US$80.7897.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0